Clinical trials: Cirrhosis Infectious
Cirrhosis, Acute Hepatitis
Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period
Liver transplantation (LT) is the only curative treatment option for patients with severe liver disease. Since 2007, the implementation of the MELD score in liver transplant allocation guidelines has led to a change in the…
- Conditions
- Cirrhosis, Acute Hepatitis, Liver, mHLA-DR
- Trial name
- PREDITH (NCT07647978)
- Testing
- blood sampling, Biocollection
- Where
- 3 sites in France
- Volunteers
- 279 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis B
Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial
This study is a randomized control prospective study. The aim of this study is to establish an all-round and convenient follow-up strategy of Chronic Hepatitis B for early detection and diagnosis of Hepatocellular Carcinoma…
- Trial name
- NCT02817685
- Testing
- 3 months, 6 months, 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI
- Where
- China
- Volunteers
- 7,660 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Cirrhosis, Chronic Liver Disease
Copper Supplementation in Cirrhosis
End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can…
- Conditions
- Cirrhosis, Chronic Liver Disease, Fibrosis, Infection
- Trial name
- NCT07471542
- Testing
- Copper Gluconate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Cirrhosis, Chronic Hepatitis C
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy…
- Trial name
- NCT00502086
- Testing
- Viusid (nutritional supplement)
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
The purpose of this Phase 2, open-label, 2-part, multicenter study was to evaluate the efficacy, safety, and pharmacokinetics of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) at different doses in…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV
- Trial name
- NCT02243280
- Testing
- ABT-493, ABT-530
- Volunteers
- 174 people
- Sponsor
- AbbVie
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
The purpose of the study is to evaluate the efficacy and safety of a treatment regimen of 12 weeks or 8 weeks of simeprevir in combination with sofosbuvir in chronic hepatitis C virus (HCV) genotype 1 infected men and women…
- Trial name
- NCT02114177
- Testing
- Simeprevir, Sofosbuvir
- Where
- 40 sites in United States, Canada
- Volunteers
- 310 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis C
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as…
- Trial name
- NCT02455167
- Testing
- Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Infection
Vector Analysis of Body Composition in Hospitalized Cirrhotic Patients
Patients with acute decompensation of cirrhosis, or acute on chronic liver failure often present with malnutrition, and due to the in-hospital stay, their nutritional intake can vary widely, with several periods of fasting, and…
- Trial name
- NCT02017301
- Testing
- Nutritional assessment
- Where
- Mexico
- Volunteers
- 79 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hepatitis C, Chronic, Liver Fibrosis
Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C
The fibrosis of liver is a complication of chronic hepatitis C. There is actually no established treatment for fibrosis of the liver. Pentoxyphilline and tocopherol may have an activity on fibrosis.
- Trial name
- NCT00119119
- Testing
- pentoxyphilline, tocopherol
- Where
- France
- Volunteers
- 100 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Vitamin D Deficiency, Infection
Vitamin D Level and Risk of Infections in Cirrhotic Patients
It is widely known that vitamin D has an important role in calcium metabolism and bone mineralization. Its deficiency is related to rickets and osteomalacia in children and adults respectively.
- Conditions
- Vitamin D Deficiency, Infection, Liver Cirrhosis
- Trial name
- NCT03391245
- Testing
- 3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique
- Where
- Egypt
- Volunteers
- 87 people
- Sponsor
- Assiut University
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
Cirrhosis
Assessment of Liver Fibrosis and Prognosis in Chinese Patients With CHB Infection Using STE/STQ Elastography
This national multicenter prospective study is aimed to study the diagnositic performance of STE/STQ elastography in liver fibrosis and prognosis in patients with chronic hepatitis B infection.
- Trial name
- NCT03530657
- Volunteers
- 460 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C Virus, Advanced Fibrosis
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to…
- Conditions
- Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
- Trial name
- COPILOT (NCT00179413)
- Testing
- PEG -Intron, Colchicine
- Where
- 49 sites in United States
- Volunteers
- 549 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis, Liver Cirrhosis
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study.
- Trial name
- NCT03892681
- Testing
- hepatocyte-specific contrast agent, extracellular contrast agent
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC